New York, NY - Researchers have made a significant breakthrough in the field of genetic testing by developing a more precise method for analyzing BRCA gene mutations. This advancement could revolutionize the way doctors assess an individual's risk of developing breast and ovarian cancer.

Two separate studies, published in the journal Nature, have outlined a new approach to classifying functional abnormalities in the BRCA2 gene. By utilizing the CRISPR-Cas9 gene-editing tool, scientists were able to accurately categorize genetic mutations and determine their impact on an individual's health.

The BRCA gene, which comes in two forms—BRCA1 and BRCA2—has been linked to an increased risk of breast and ovarian cancer, as well as other cancers such as prostate and pancreatic cancer. While BRCA testing has become more common since actress Angelina Jolie underwent a preventive mastectomy in 2013, the accuracy of these tests has been a subject of debate.

Prior to this research, many genetic mutations identified in the BRCA gene were classified as "variants of unknown significance" (VUS). This meant that it was unclear whether these mutations would actually lead to the development of cancer. As a result, individuals who carried these VUS were often left uncertain about their risk.

The new studies, conducted by teams led by Sham Sharran at the National Cancer Institute and Fergus Couch at Mayo Clinic, have developed a more accurate way to classify these mutations. By introducing various BRCA2 gene mutations into laboratory models and observing their effects, the researchers were able to determine which mutations were harmful and which were benign.

"This research has filled a significant gap in our understanding of BRCA2 gene mutations," said Kyung-sik Park, a professor at the Breast Cancer Center at Konkuk University Hospital. "Previously, we lacked the data to accurately assess the risk associated with thousands of identified mutations. Now, we can classify these mutations based on their functional significance."

The development of this new testing method is largely attributed to advancements in CRISPR-Cas9 gene-editing technology. This powerful tool allows scientists to precisely target and modify specific genes, making it ideal for studying the effects of genetic mutations.

"The BRCA2 gene is very delicate, and it's easy to damage during the genetic engineering process," said Ji-su Park, a professor of oncology at Severance Hospital. "It's remarkable that this technology has been developed within just five years of the initial concept."

With this new testing method, individuals can receive a more accurate assessment of their cancer risk, allowing them to make more informed decisions about their healthcare. Additionally, this breakthrough could lead to the development of new targeted therapies for individuals with harmful BRCA mutations.